tiprankstipranks
Urologix (ULGX)
OTHER OTC:ULGX
US Market

Urologix (ULGX) Income Statement

6 Followers

Urologix Income Statement

Last quarter (Q ), Urologix's total revenue was $2.80M, a decrease of -16.69% from the same quarter last year. In Q, Urologix's net income was $-349.00K. See Urologix’s key income statements, including revenue, expenses, profit, and income.
Income Statement
TTM
Jun 14Jun 13Jun 12Jun 11Jun 10
Total Revenue
$ 12.19M$ 14.23M$ 16.59M$ 17.03M$ 12.57M$ 14.77M
Cost of Revenue
$ 6.37M$ 8.14M$ 8.41M$ 8.64M$ 6.03M$ 6.57M
Gross Profit
$ 5.82M$ 6.09M$ 8.18M$ 8.38M$ 6.54M$ 8.20M
Operating Expense
$ 6.72M$ 10.09M$ 12.71M$ 12.53M$ 10.27M$ 10.46M
Operating Income
$ -900.00K$ -4.00M$ -4.53M$ -4.14M$ -3.73M$ -2.26M
Net Non Operating Interest Income Expense
$ -771.00K$ -693.00K$ -555.00K$ -482.00K$ 1.00K$ 0.00
Other Income Expense
$ -3.05M$ -2.93M$ 807.00K$ -13.00K--
Pretax Income
$ -4.72M$ -7.62M$ -4.28M$ -4.64M$ -3.73M$ -2.26M
Tax Provision
$ -53.00K$ -16.00K$ 14.00K$ 55.00K$ 8.00K$ -88.00K
Earnings From Equity Interest Net Of Tax
------
Net Income Common Stockholders
$ -4.67M$ -7.61M$ -4.29M$ -4.70M$ -3.73M$ -2.17M
Basic EPS
$ -0.23$ -0.36$ -0.21$ -0.32$ -0.26$ -0.15
Diluted EPS
$ -0.23$ -0.36$ -0.21$ -0.32$ -0.26$ -0.15
Basic Average Shares
$ 86.40M$ 21.22M$ 20.70M$ 14.74M$ 14.56M$ 14.51M
Diluted Average Shares
$ 86.40M$ 21.22M$ 20.70M$ 14.74M$ 14.56M$ 14.51M
Dividend Per Share
------
Total Operating Income As Reported
------
Reported Normalized Basic E P S
------
Reported Normalized Diluted E P S
------
Rent Expense Supplemental
------
Total Expenses
$ 13.09M$ 18.23M$ 21.12M$ 21.17M$ 16.30M$ 17.03M
Net Income From Continuing And Discontinued Operation
$ -4.67M$ -7.61M$ -4.29M$ -4.70M$ -3.73M$ -2.17M
Normalized Income
$ -1.62M$ -4.68M$ -5.10M$ -4.68M$ -3.73M$ -2.17M
Interest Expense
$ 771.00K$ 693.00K$ 555.00K$ 482.00K--
EBIT
$ -1.02M$ -4.00M$ -4.53M$ -4.14M$ -3.73M$ -2.26M
EBITDA
$ -517.00K$ -3.41M$ -3.86M$ -3.45M$ -3.16M$ -1.46M
Currency in USD

Urologix Earnings and Revenue History

What's Included in PREMIUM?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis